Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity. Phase 1 study of DK210 (EGFR), a tumor-targeted IL2 x IL10 dual ...
New findings reveal how cancer manipulates immune pathways and highlight therapeutic strategies to unleash T-cells against even the most resistant tumors. Study: Cancer cells impair monocyte-mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results